Updated time: 2021-02-25 10:43:03
12A-1061101
TW I694993、US 10894037 B2
We employed computer-aided drug design, biophysical and biochemical techniques to identify potential inhibitors targeting the PmrA/PmrB two component system of Klebsiella pneumoniae (KP). This inhibitor was observed to be able to restore the susceptibility of KP to polymyxin B in our microbial viability assay. Therefore, the identified inhibitor is of great potential in developing the new antibacterial agent for clinic trial.
Conventional antibiotics directly inhibit the protein which is functionally important for the growth and survival of bacteria. Thus, this kind of antibiotics usually forces bacteria to mutate to a drug resistant stain, in order to survive. While the function of inhibitor, targeting two component system (TCS), is to inhibit the upstream regulatory control, not the downstream activities. Hence, the TCS inhibitor will not easily cause the mutation of bacteria. The anti-TCS drug is possible to develop as a new pesticide. The TCS inhibitor that we identified could be a new type of antibiotics or function as an adjuvant to restore the susceptibility of drug resistant bacteria to antibiotics.
New type of antibiotic.
Adjuvant which combines with known antibiotics to treat the multi-drug resistant bacteria.
Chinpan Chen, Tien-Sheng Tseng, Keng-Chang Tsai
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Inhibitors of bacterial two component signal transduction system and uses thereof